The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

Knowledge of the association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (OPSCC) is ...

The FDA has approved cosibelimab under the brand name Unloxcyt for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC that’s not curable by surgery or ...

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...